Zenibast-M Tablet contains a combination of Ebastine 10 mg and Montelukast 10 mg, formulated for the management of allergic conditions. Ebastine is a second-generation antihistamine that selectively antagonizes peripheral H1 receptors, effectively alleviating symptoms such as sneezing, nasal congestion, rhinorrhea, and pruritus associated with allergic rhinitis and chronic urticaria. Montelukast is a leukotriene receptor antagonist that inhibits the cysteinyl leukotriene receptor, thereby reducing inflammation, bronchoconstriction, and mucus secretion commonly observed in asthma and allergic rhinitis. The synergistic action of these two agents provides comprehensive relief from both upper and lower respiratory allergic manifestations. Zenibast-M is indicated for the treatment of seasonal and perennial allergic rhinitis, chronic idiopathic urticaria, and as an adjunct in asthma management to improve symptom control and reduce exacerbations. The combination improves patient compliance by reducing pill burden while offering effective symptom relief. It is generally well-tolerated, with a safety profile consistent with its individual components; common adverse effects may include headache, dizziness, and gastrointestinal disturbances. Caution is advised in patients with hepatic impairment, and it should be used under medical supervision, especially in pediatric and elderly populations.